Drug intelligence / Profile preview

parecoxib + flurbiprofen axetil

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of two non-steroidal anti-inflammatory drugs (NSAIDs) used for perioperative pain management. Parecoxib is a selective COX-2 inhibitor while flurbiprofen axetil is a non-selective NSAID delivered via lipid microspheres. The combination provides complementary analgesic coverage, with parecoxib being most effective at 0, 0.5, 1, 6, 8, and 24 hours postoperatively, while flurbiprofen axetil shows peak efficacy at 2, 4, and 12 hours. Both drugs reduce postoperative pain, inflammation, and the incidence of adverse events compared to other analgesics.

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on parecoxib + flurbiprofen axetil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on parecoxib + flurbiprofen axetil.

Explore the full profile